Latest Nanotechnology News

Dotz Nano Limited has raised an additional A$460,000 through unsecured loans, bringing total funding under this facility to A$1.2 million to support working capital needs.

Dotz Nano has secured its first commercial order for its innovative Amine-Modified Polymer CO2 sorbent from a leading automotive innovation hub, marking a key step toward commercial deployment in sustainable aviation fuel production.

Dotz Nano Limited has raised approximately A$740,000 through unsecured loans featuring convertible options, aiming to bolster its working capital amid ongoing funding efforts.

Dotz Nano has responded to an ASX price query following unusual trading activity, confirming no undisclosed information and reaffirming compliance with continuous disclosure rules.

Dotz Nano Limited reported a reduced half-year loss and significant progress in its Direct Air Capture technology, while navigating funding uncertainties with key investors.

Locksley Resources has partnered with Rice University to pioneer domestic antimony processing in the US, aiming to reduce reliance on foreign supply and support critical defense and energy sectors.

Imagion Biosystems has raised A$3.5 million through a placement to fund its Phase 2 clinical trial for HER2+ Breast Cancer in the US, marking a significant step in advancing its proprietary MagSense® imaging technology.

Adisyn Ltd has made significant strides in developing low-temperature graphene semiconductor interconnects, commissioning a new Atomic Layer Deposition system and securing a major managed IT services contract, while maintaining a strong cash position.

Adisyn Ltd has commissioned a cutting-edge Atomic Layer Deposition system at its Israeli research hub, enhancing its graphene semiconductor development alongside a parallel unit at Tel Aviv University.

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

Imagion Biosystems has received encouraging feedback from the FDA on its planned Phase 2 HER2 breast cancer clinical trial, paving the way for its Investigational New Drug application submission later this year.

Dotz Nano Limited has announced a A$1.2 million private placement at a discounted share price, accompanied by options, to bolster working capital and support the commercialisation of its carbon capture technology.